CoChat

Exenatide

Bray, Grant M. · 2006 · American Journal of Health-System Pharmacy

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of exenatide are discussed. SUMMARY: Exenatide, derived from a compound found in the saliva of the Gila monster, is an incretin mimetic agent that enhances glucose-dependent insulin secretion and has several other antihyperglycemic actions. The drug is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or both but who have not achieved adequate glycemic control. Peak plasma concentration following subcutaneous administration of exenatide is attained in 2.1 hours. The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L. The terminal half-life of the drug is 2.4 hours. Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%. The drug is predominantly eliminated by glomerular filtration followed by proteolytic degradation. Clinical trials have shown that exenatide given subcutaneously twice daily significantly reduced glycosylated hemoglobin values when maximum doses of a sulfonylurea, metformin, or both were ineffective. The most common adverse effects are nausea, vomiting, diarrhea, jitteriness, dizziness, headache, and dyspepsia. Drug-drug interactions with digoxin, lovastatin, lisinopril, and acetaminophen have been documented. The recommended starting dosage is 5 microg subcutaneously twice daily within one hour before the morning and evening meals. CONCLUSION: Exenatide offers a novel treatment option for patients with type 2 diabetes mellitus who are refractory to metformin or sulfonylurea therapy or both.

Overview

Integrity signals

Registry

Crossref · 10.2146/ajhp050459

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. 2000, Endocrinology, 141, 1936, 10.1210/endo.141.6.7490 · doi:10.1210/endo.141.6.7490 · Paper page

Cited by

See all 52

Metadata

Authors
Bray, G. M.
Affiliations
Denver Health Medical Center (US)
Corresponding author
Bray, Grant M.
Venue
American Journal of Health-System Pharmacy
Published
2006-03-01
Volume
63
Issue
5
Pages
411-418
ISSN
  • 1079-2082 (ISSN-L)
  • 1535-2900
OpenAlex
W4233375494
Cited by
52
References
26
Citations by year
2026: 5 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 2 · 2016: 1 · 2014: 3 · 2013: 4 · 2012: 1
FWCI
0.37
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Health-System Pharmacy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
exenatide, incretin mimetics, type 2 diabetes, glycemic control, glucose-dependent insulin secretion, pharmacokinetics, adverse drug reactions, drug-drug interactions, metformin, sulfonylureas, HbA1c
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Interactions, Humans, Hypoglycemic Agents, Peptides, Venoms, Receptors, Glucagon

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.